Storia in 11 fonti

Novartis shares plummet after another clinical trial setback

Shares in the market heavyweight plummeted by over 10% at one point during early trading on Tuesday following the failure of a trial into a drug for a muscle disorder.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

swissinfo.chStai leggendo2 g fa

Novartis shares plummet after another clinical trial setback

Shares in the market heavyweight plummeted by over 10% at one point during early trading on Tuesday following the failure of a trial into a drug for a muscle disorder.

originale

Timeline cronologica

martedì 8 settembre 2026·cnbc.com
Pharma major Novartis falls 10% after three drug trial setbacks
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
martedì 8 settembre 2026·endpoints.news
Updated: Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug
Novartis' del-desiran misses HARBOR trial's primary endpoint, adding to pelacarsen miss and CAR-T deaths; shares sink 10%.

Novartis shares plummet after another clinical trial setback

Confronto fonti

Novartis shares plummet after another clinical trial setback

Timeline cronologica

Pharma major Novartis falls 10% after three drug trial setbacks

Updated: Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug

Pharma major Novartis falls 10% after three drug trial setbacks

Novartis secoué en bourse après une succession d’échecs cliniques - Le Temps

Novartis del-desiran drug trial fails, stock drops 9%

Novartis verliert 24 Milliarden Börsenwert nach Medikamenten-Rückschlägen

Updated: Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug

Novartis erleidet weiteren Rückschlag in der Forschung. Aktie verliert über 10 Prozent

Novartis Sees Avidity Drug Fail in Third Setback in a Week

A Zurigo affonda Novartis, nuovo flop su farmaco muscolare sperimentale

Tercer revés para Novartis en pocos días: la farmacéutica se derrumba en Bolsa tras los malos resultados de un medicamento muscular

Novartis del-desiran drug trial fails, stock drops 9%

Novartis shares plummet after another clinical trial setback

Novartis verliert 24 Milliarden Börsenwert nach Medikamenten-Rückschlägen

Nach Studienfehlschlägen: Aktien von Novartis stehen vor Bewährungsprobe

Novartis secoué en bourse après une succession d’échecs cliniques - Le Temps

Major Novartis shareholder calls for board shake-up after drug trial setbacks